TTR and hydrops fetalis: The ongoing phase III DEPLETE-TTR trial (NCT06183931) is designed to investigate the safety and efficacy of ALXN2220 (new name for NI006) in patients with ATTR-CM, either ATTRwt-CM or ATTRv-CM, with an NTproBNP > 2000 ng/L and a history of HF; in case of positive results, the mAb approach could truly revolutionise the therapy for patients with ATTR-CM.